Your browser doesn't support javascript.
loading
Growth hormone deficit. Does the first year of treatment influence adult height?
Sánchez Malo, María José; Hidalgo Sanz, Juan; Hernández Abadía, Rebeca; Arlabán Carpintero, Leire; Ferrer Lozano, Marta; Labarta Aizpún, Jose Ignacio; de Arriba Muñoz, Antonio.
Afiliação
  • Sánchez Malo MJ; Servicio de Pediatría, Hospital Reina Sofía, Tudela, Navarra, Spain. Electronic address: mjsanchezmalo@gmail.com.
  • Hidalgo Sanz J; Servicio de Pediatría, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Hernández Abadía R; Servicio de Pediatría, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Arlabán Carpintero L; Servicio de Pediatría, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Ferrer Lozano M; Unidad de Endocrinología Pediátrica, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Labarta Aizpún JI; Unidad de Endocrinología Pediátrica, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • de Arriba Muñoz A; Unidad de Endocrinología Pediátrica, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Endocrinol Diabetes Nutr (Engl Ed) ; 68(8): 534-541, 2021 Oct.
Article em En | MEDLINE | ID: mdl-34872636
ABSTRACT

INTRODUCTION:

Short stature is the most frequent reason for Pediatric Endocrinology consultations and sometimes requires treatment with growth hormone.

OBJECTIVE:

The possible correlation of a good response to any early response factor with a better final response was studied, and also whether there was a difference in response to treatment according to the type of deficit. PATIENTS AND

METHODS:

This was a longitudinal, retrospective and observational study of 139 patients treated for idiopathic growth hormone deficiency up to adult height. There were good response criteria in the first year of treatment a) an increase in growth rate ≥3 cm/year, b) a growth rate ≥1 standard deviation (SD), c) an increase in height ≥0.5 SD, d) an increase in height ≥0.3 SD. Study of the Index of Responsiveness to treatment in the first and second year. Final response variables adult height with respect to target height, adult height with respect to initial growth prediction and adult height with respect to initial height at the start of treatment. The possible correlation of a good response to any of the early response factors with a better final response to treatment was studied, and also whether there was a difference in the response to treatment according to the type of deficit.

RESULTS:

The treatment produced a gain in adult height with respect to genetic height of 0.06 ±â€¯0.7 SD. Patients considered good responders in the first year of treatment presented a better final response (growth rate ≥3 cm p = 0.000, growth rate ≥1 SD p = 0.008, height gain ≥0.5 SD p = 0.007, height gain ≥0.3 SD p = 0.006), as well as patients with a severe deficit (p = 0.04). The index of responsiveness to treatment during the first year was associated with a better final response (r = 0.249, p = 0.003), with this correlation being maintained in the second year (r = 0.294, p = 0.01).

CONCLUSIONS:

Growth hormone treatment increased height in the genetic target. The percentage of good responders varied depending on the criteria used. The response in the first year of treatment and a severe deficit were determining factors for achieving a good long-term response.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hormônio do Crescimento Humano / Nanismo Hipofisário Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Child / Humans Idioma: En Revista: Endocrinol Diabetes Nutr (Engl Ed) Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hormônio do Crescimento Humano / Nanismo Hipofisário Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Child / Humans Idioma: En Revista: Endocrinol Diabetes Nutr (Engl Ed) Ano de publicação: 2021 Tipo de documento: Article